Comments
Loading...

Vertex Pharmaceuticals Analyst Ratings

VRTXNASDAQ
Logo brought to you by Benzinga Data
$460.06
7.621.68%
At close: -
$460.06
0.000.00%
After Hours: 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$583.00
Lowest Price Target1
$423.00
Consensus Price Target1
$512.42

Vertex Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:VRTX | Benzinga

Vertex Pharmaceuticals Inc has a consensus price target of $512.42 based on the ratings of 28 analysts. The high is $583 issued by UBS on February 11, 2025. The low is $423 issued by RBC Capital on May 6, 2025. The 3 most-recent analyst ratings were released by RBC Capital, Scotiabank, and Morgan Stanley on May 6, 2025, respectively. With an average price target of $443 between RBC Capital, Scotiabank, and Morgan Stanley, there's an implied -3.71% downside for Vertex Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
6
2
Feb
1
Mar
1
Apr
2
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.1
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

RBC Capital
Scotiabank
Morgan Stanley
JP Morgan
Cantor Fitzgerald

1calculated from analyst ratings

Analyst Ratings for Vertex Pharmaceuticals

Buy NowGet Alert
05/06/2025Buy Now-8.06%RBC Capital
Brian Abrahams50%
$420 → $423MaintainsSector PerformGet Alert
05/06/2025Buy Now-3.93%Scotiabank
Greg Harrison50%
$450 → $442MaintainsSector PerformGet Alert
05/06/2025Buy Now0.86%Morgan Stanley
Matthew Harrison61%
$462 → $464MaintainsEqual-WeightGet Alert
05/06/2025Buy Now11.94%JP Morgan
Jessica Fye66%
$512 → $515MaintainsOverweightGet Alert
05/06/2025Buy Now16.29%Cantor Fitzgerald
Carter Gould55%
$535 → $535ReiteratesOverweight → OverweightGet Alert
05/06/2025Buy NowNeedham
Joseph Stringer62%
ReiteratesHold → HoldGet Alert
05/06/2025Buy Now9.33%Leerink Partners
David Risinger72%
$550 → $503DowngradeOutperform → Market PerformGet Alert
04/22/2025Buy Now16.29%Cantor Fitzgerald
Carter Gould55%
→ $535Assumes → OverweightGet Alert
04/01/2025Buy Now-8.71%RBC Capital
Brian Abrahams50%
$408 → $420MaintainsSector PerformGet Alert
03/31/2025Buy Now23.24%B of A Securities
Ying Huang58%
$555 → $567MaintainsBuyGet Alert
02/20/2025Buy Now-11.32%RBC Capital
Brian Abrahams50%
$407 → $408MaintainsSector PerformGet Alert
02/12/2025Buy Now-7.84%Canaccord Genuity
Whitney Ijem59%
$408 → $424UpgradeSell → HoldGet Alert
02/11/2025Buy Now26.72%UBS
Colin Bristow40%
$586 → $583MaintainsBuyGet Alert
02/11/2025Buy Now20.64%B of A Securities
Ying Huang58%
$540 → $555MaintainsBuyGet Alert
02/11/2025Buy Now13.03%Truist Securities
Joon Lee77%
$460 → $520MaintainsBuyGet Alert
02/11/2025Buy Now-11.53%RBC Capital
Brian Abrahams50%
$402 → $407MaintainsSector PerformGet Alert
02/11/2025Buy Now-2.19%Scotiabank
Greg Harrison50%
$433 → $450MaintainsSector PerformGet Alert
02/11/2025Buy Now4.33%Cantor Fitzgerald
Olivia Brayer53%
$480 → $480ReiteratesOverweight → OverweightGet Alert
02/11/2025Buy Now1.51%Barclays
Gena Wang63%
$435 → $467MaintainsEqual-WeightGet Alert
02/11/2025Buy Now19.55%HC Wainwright & Co.
Andrew Fein63%
$550 → $550ReiteratesBuy → BuyGet Alert
02/11/2025Buy Now-0.23%Morgan Stanley
Matthew Harrison61%
$450 → $459MaintainsEqual-WeightGet Alert
02/11/2025Buy NowNeedham
Joseph Stringer62%
ReiteratesHold → HoldGet Alert
02/04/2025Buy Now17.38%B of A Securities
Ying Huang58%
$522 → $540MaintainsBuyGet Alert
01/31/2025Buy Now-5.45%Barclays
Gena Wang63%
$418 → $435MaintainsEqual-WeightGet Alert
01/31/2025Buy Now18.46%BMO Capital
Evan Seigerman62%
$520 → $545MaintainsOutperformGet Alert
01/31/2025Buy Now4.33%Cantor Fitzgerald
Olivia Brayer53%
$480 → $480ReiteratesOverweight → OverweightGet Alert
01/31/2025Buy Now-5.88%Scotiabank
Greg Harrison50%
$430 → $433MaintainsSector PerformGet Alert
01/31/2025Buy Now19.55%HC Wainwright & Co.
Andrew Fein63%
$535 → $550MaintainsBuyGet Alert
01/31/2025Buy NowNeedham
Joseph Stringer62%
ReiteratesHold → HoldGet Alert
01/30/2025Buy Now-0.01%Wells Fargo
Mohit Bansal67%
$460 → $460DowngradeOverweight → Equal-WeightGet Alert
01/27/2025Buy Now15.85%Piper Sandler
Christopher Raymond55%
$535 → $533MaintainsOverweightGet Alert
01/24/2025Buy Now4.33%Cantor Fitzgerald
Olivia Brayer53%
$480 → $480ReiteratesOverweight → OverweightGet Alert
01/10/2025Buy Now-0.01%Wells Fargo
Mohit Bansal67%
$555 → $460MaintainsOverweightGet Alert
12/23/2024Buy Now-0.01%Truist Securities
Joon Lee77%
$550 → $460MaintainsBuyGet Alert
12/23/2024Buy Now-6.53%Scotiabank
Greg Harrison50%
$426 → $430MaintainsSector PerformGet Alert
12/23/2024Buy Now8.68%JP Morgan
Jessica Fye66%
$503 → $500MaintainsOverweightGet Alert
12/20/2024Buy Now-9.14%Barclays
Gena Wang63%
$509 → $418MaintainsEqual-WeightGet Alert
12/20/2024Buy Now13.03%BMO Capital
Evan Seigerman62%
$566 → $520MaintainsOutperformGet Alert
12/20/2024Buy NowNeedham
Joseph Stringer62%
ReiteratesHold → HoldGet Alert
12/20/2024Buy Now16.29%HC Wainwright & Co.
Andrew Fein63%
$600 → $535MaintainsBuyGet Alert
12/19/2024Buy NowOppenheimer
Hartaj Singh46%
DowngradeOutperform → PerformGet Alert
12/19/2024Buy Now13.46%B of A Securities
Ying Huang58%
$545 → $522MaintainsBuyGet Alert
12/16/2024Buy Now7.38%Stifel
Paul Matteis45%
$490 → $494MaintainsHoldGet Alert
12/09/2024Buy Now19.55%Jefferies
Michael Yee56%
$500 → $550UpgradeHold → BuyGet Alert
11/14/2024Buy Now24.98%Citigroup
Geoff Meacham63%
→ $575Initiates → BuyGet Alert
11/06/2024Buy Now-11.32%Canaccord Genuity
Whitney Ijem59%
$361 → $408MaintainsSellGet Alert
11/05/2024Buy Now5.64%Scotiabank
Greg Harrison50%
$480 → $486MaintainsSector PerformGet Alert
11/05/2024Buy Now27.37%UBS
Colin Bristow40%
$562 → $586MaintainsBuyGet Alert
11/05/2024Buy Now4.33%Cantor Fitzgerald
Olivia Brayer53%
$480 → $480ReiteratesOverweight → OverweightGet Alert
11/05/2024Buy Now-1.97%RBC Capital
Brian Abrahams50%
$437 → $451MaintainsSector PerformGet Alert
11/05/2024Buy Now9.33%JP Morgan
Jessica Fye66%
$510 → $503MaintainsOverweightGet Alert
11/05/2024Buy Now3.46%Morgan Stanley
Matthew Harrison61%
$473 → $476MaintainsEqual-WeightGet Alert
10/30/2024Buy Now17.38%Oppenheimer
Hartaj Singh46%
$550 → $540MaintainsOutperformGet Alert
10/21/2024Buy Now30.42%HC Wainwright & Co.
Andrew Fein63%
$600 → $600ReiteratesBuy → BuyGet Alert
10/17/2024Buy Now22.16%UBS
Colin Bristow40%
$477 → $562MaintainsBuyGet Alert
10/16/2024Buy Now4.33%Scotiabank
Greg Harrison50%
→ $480Initiates → Sector PerformGet Alert
10/14/2024Buy Now17.59%B of A Securities
Ying Huang58%
$550 → $541MaintainsBuyGet Alert
10/10/2024Buy NowRaymond James
Danielle Brill44%
Reinstates → Market PerformGet Alert
10/09/2024Buy Now-5.01%RBC Capital
Brian Abrahams50%
$425 → $437MaintainsSector PerformGet Alert
10/08/2024Buy Now4.33%Cantor Fitzgerald
Olivia Brayer53%
$480 → $480ReiteratesOverweight → OverweightGet Alert
10/04/2024Buy Now-7.62%RBC Capital
Brian Abrahams50%
$431 → $425MaintainsSector PerformGet Alert
10/01/2024Buy Now3.03%Morgan Stanley
Matthew Harrison61%
$462 → $474MaintainsEqual-WeightGet Alert
09/19/2024Buy Now-6.32%RBC Capital
Brian Abrahams50%
$431 → $431ReiteratesSector Perform → Sector PerformGet Alert
08/05/2024Buy Now30.42%HC Wainwright & Co.
Andrew Fein63%
$500 → $600MaintainsBuyGet Alert
08/05/2024Buy Now19.55%Oppenheimer
Hartaj Singh46%
$500 → $550MaintainsOutperformGet Alert
08/05/2024Buy Now10.86%JP Morgan
Jessica Fye66%
$505 → $510MaintainsOverweightGet Alert
08/05/2024Buy Now19.55%Truist Securities
Joon Lee77%
$508 → $550ReiteratesBuy → BuyGet Alert
08/05/2024Buy Now10.64%Barclays
Gena Wang63%
$472 → $509DowngradeOverweight → Equal-WeightGet Alert
08/02/2024Buy Now11.94%Evercore ISI Group
Liisa Bayko70%
$438 → $515MaintainsOutperformGet Alert
08/02/2024Buy Now21.29%Guggenheim
Debjit Chattopadhyay56%
$450 → $558MaintainsBuyGet Alert
08/02/2024Buy Now4.33%Cantor Fitzgerald
Olivia Brayer53%
$480 → $480ReiteratesOverweight → OverweightGet Alert
08/02/2024Buy Now16.29%Piper Sandler
Christopher Raymond55%
$500 → $535MaintainsOverweightGet Alert
07/31/2024Buy Now-18.27%Canaccord Genuity
Whitney Ijem59%
$371 → $376MaintainsSellGet Alert
07/26/2024Buy NowNeedham
Joseph Stringer62%
Reiterates → HoldGet Alert
07/23/2024Buy Now8.68%TD Cowen
Phil Nadeau66%
$450 → $500MaintainsBuyGet Alert
07/22/2024Buy Now4.33%Cantor Fitzgerald
Olivia Brayer53%
$440 → $480MaintainsOverweightGet Alert
07/19/2024Buy Now8.68%HC Wainwright & Co.
Andrew Fein63%
$462 → $500MaintainsBuyGet Alert
07/11/2024Buy Now-1.1%Morgan Stanley
Matthew Harrison61%
$402 → $455MaintainsEqual-WeightGet Alert
06/27/2024Buy Now18.46%Redburn Atlantic
Steve Chesney53%
→ $545Initiates → BuyGet Alert
06/24/2024Buy Now20.64%Wells Fargo
Mohit Bansal67%
$540 → $555MaintainsOverweightGet Alert
06/17/2024Buy Now19.55%Argus Research
Jasper Hellweg68%
$465 → $550MaintainsBuyGet Alert
06/11/2024Buy Now-8.49%RBC Capital
Brian Abrahams50%
$424 → $421MaintainsSector PerformGet Alert
06/04/2024Buy Now-7.84%RBC Capital
Brian Abrahams50%
$424 → $424ReiteratesSector Perform → Sector PerformGet Alert
05/31/2024Buy Now8.68%BMO Capital
Evan Seigerman62%
$480 → $500MaintainsOutperformGet Alert
05/07/2024Buy Now0.42%HC Wainwright & Co.
Andrew Fein63%
$462 → $462ReiteratesBuy → BuyGet Alert
05/07/2024Buy Now-7.84%RBC Capital
Brian Abrahams50%
$417 → $424MaintainsSector PerformGet Alert
05/07/2024Buy Now-0.88%Piper Sandler
Christopher Raymond55%
$450 → $456MaintainsOverweightGet Alert
05/07/2024Buy NowNeedham
Joseph Stringer62%
Reiterates → HoldGet Alert
04/18/2024Buy Now-2.19%Guggenheim
Debjit Chattopadhyay56%
$445 → $450MaintainsBuyGet Alert
04/17/2024Buy Now1.29%UBS
Colin Bristow40%
$498 → $466MaintainsBuyGet Alert
04/15/2024Buy Now8.68%Oppenheimer
Hartaj Singh46%
→ $500MaintainsOutperformGet Alert
04/12/2024Buy Now-19.36%Canaccord Genuity
Whitney Ijem59%
$371 → $371MaintainsSellGet Alert
04/11/2024Buy Now0.42%HC Wainwright & Co.
Andrew Fein63%
$457 → $462MaintainsBuyGet Alert
04/11/2024Buy Now-4.8%Evercore ISI Group
Liisa Bayko70%
→ $438UpgradeIn-Line → OutperformGet Alert
02/20/2024Buy Now-4.36%Cantor Fitzgerald
Olivia Brayer53%
$440 → $440ReiteratesOverweight → OverweightGet Alert
02/15/2024Buy NowWolfe Research
Andy Chen48%
Initiates → OutperformGet Alert
02/06/2024Buy Now-4.36%Cantor Fitzgerald
Olivia Brayer53%
$440 → $440ReiteratesOverweight → OverweightGet Alert
02/06/2024Buy Now-2.19%JP Morgan
Jessica Fye66%
$438 → $450MaintainsOverweightGet Alert
02/06/2024Buy Now17.38%Wells Fargo
Mohit Bansal67%
$500 → $540MaintainsOverweightGet Alert
02/06/2024Buy Now-8.71%RBC Capital
Brian Abrahams50%
$397 → $420MaintainsSector PerformGet Alert

FAQ

Q

What is the target price for Vertex Pharmaceuticals (VRTX) stock?

A

The latest price target for Vertex Pharmaceuticals (NASDAQ:VRTX) was reported by RBC Capital on May 6, 2025. The analyst firm set a price target for $423.00 expecting VRTX to fall to within 12 months (a possible -8.06% downside). 81 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Vertex Pharmaceuticals (VRTX)?

A

The latest analyst rating for Vertex Pharmaceuticals (NASDAQ:VRTX) was provided by RBC Capital, and Vertex Pharmaceuticals maintained their sector perform rating.

Q

When was the last upgrade for Vertex Pharmaceuticals (VRTX)?

A

The last upgrade for Vertex Pharmaceuticals Inc happened on February 12, 2025 when Canaccord Genuity raised their price target to $424. Canaccord Genuity previously had a sell for Vertex Pharmaceuticals Inc.

Q

When was the last downgrade for Vertex Pharmaceuticals (VRTX)?

A

The last downgrade for Vertex Pharmaceuticals Inc happened on May 6, 2025 when Leerink Partners changed their price target from $550 to $503 for Vertex Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Vertex Pharmaceuticals (VRTX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vertex Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vertex Pharmaceuticals was filed on May 6, 2025 so you should expect the next rating to be made available sometime around May 6, 2026.

Q

Is the Analyst Rating Vertex Pharmaceuticals (VRTX) correct?

A

While ratings are subjective and will change, the latest Vertex Pharmaceuticals (VRTX) rating was a maintained with a price target of $420.00 to $423.00. The current price Vertex Pharmaceuticals (VRTX) is trading at is $460.06, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch